See more : Llorente & Cuenca, S.A. (LLYC.MC) Income Statement Analysis – Financial Results
Complete financial analysis of Vaxil Bio Ltd. (VXL.V) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vaxil Bio Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Plasto-Cargal Group Ltd (PLCR.TA) Income Statement Analysis – Financial Results
- Shinobu Foods Products Co., Ltd. (2903.T) Income Statement Analysis – Financial Results
- ICICI Lombard General Insurance Company Limited (ICICIGI.BO) Income Statement Analysis – Financial Results
- Cree, Inc. (CREE) Income Statement Analysis – Financial Results
- Rockhaven Resources Ltd. (RKHNF) Income Statement Analysis – Financial Results
Vaxil Bio Ltd. (VXL.V)
About Vaxil Bio Ltd.
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment and a coronavirus (COVID-19) vaccine. The company has a collaboration agreement with The Tel Aviv Sourasky Medical Center for the company's research program to develop a potential peptide vaccine against COVID-19; and cooperative research and development agreement with U.S. Army Medical Research Institute of Infectious Diseases for testing CorVax for its ability to prevent COVID-19 in mice. The company was founded in 2006 and is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 2.00K | 25.00K | 57.00K | 100.00K | 56.00K | 47.00K | 22.00K | 9.00K | 11.00 | 4.85K | 4.57K | 241.87K | 183.07K | 6.12K |
| Gross Profit | 0.00 | -2.00K | -25.00K | -57.00K | -100.00K | -56.00K | -47.00K | -22.00K | -9.00K | -11.00 | -4.85K | -4.57K | -241.87K | -183.07K | -6.12K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 114.00K | 343.00K | 539.00K | 619.00K | 750.00K | 575.00K | 838.00K | 585.00K | 345.00K | 681.00 | 1.31K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 100.00K | 239.00K | 428.00K | 724.00K | 383.00K | 466.00K | 965.00K | 3.90M | 725.00K | 1.23K | 362.32K | 373.59K | 269.92K | 257.09K | 154.71K |
| Selling & Marketing | 40.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 31.00 | 11.08K | 0.00 | 8.22K | 6.09K | 104.00 |
| SG&A | 140.00K | 239.00K | 428.00K | 724.00K | 383.00K | 466.00K | 965.00K | 3.90M | 725.00K | 1.26K | 373.41K | 373.59K | 278.14K | 263.18K | 154.81K |
| Other Expenses | 0.00 | 2.00K | 19.00K | 4.00K | 10.00K | 0.00 | 0.00 | -19.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 254.00K | 584.00K | 986.00K | 1.35M | 1.14M | 1.04M | 1.80M | 4.49M | 1.07M | 1.78K | 373.41K | 373.59K | 278.14K | 263.18K | 154.81K |
| Cost & Expenses | 254.00K | 584.00K | 986.00K | 1.35M | 1.14M | 1.04M | 1.80M | 4.49M | 1.07M | 1.79K | 378.26K | 378.16K | 520.01K | 446.24K | 160.93K |
| Interest Income | 0.00 | 0.00 | 0.00 | 11.00 | 11.00 | 0.00 | 10.00K | 0.00 | 61.00 | 0.00 | 4.00 | 566.00 | 1.51K | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 11.00K | 11.00K | 0.00 | 10.00K | 3.00K | 0.00 | 0.00 | 55.13K | 0.00 | -1.51K | 0.00 | |
| Depreciation & Amortization | 167.90K | 2.00K | 25.00K | 57.00K | 100.00K | 56.00K | 47.00K | 22.00K | 8.00K | 257.00 | -75.55K | 55.13K | 0.00 | 0.00 | 0.00 |
| EBITDA | -254.00K | -582.00K | -961.00K | -1.29M | -1.04M | -985.00K | -1.76M | -1.69M | -1.06M | -1.42M | -453.80K | -323.03K | -520.01K | -446.24K | -160.93K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -254.00K | -584.00K | -986.00K | -1.35M | -1.14M | -1.04M | -1.80M | -4.55M | -1.07M | -1.67K | -378.26K | -378.16K | -520.01K | -446.24K | -160.93K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | 0.00 | 0.00 | -11.00K | -11.00K | -6.00K | 5.00K | 10.00K | -3.00K | -178.00 | 75.55K | -55.13K | 566.00 | 1.51K | 0.00 |
| Income Before Tax | -254.00K | -584.00K | -986.00K | -1.36M | -1.15M | -1.05M | -1.80M | -4.54M | -1.07M | -1.85K | -302.71K | -433.28K | -519.45K | -444.74K | -160.93K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 11.00K | 11.00K | 6.00K | -5.00K | 100.00K | 3.00K | 0.00 | -75.55K | -5.00K | -566.00 | -62.99K | 0.00 |
| Net Income | -254.00 | -584.00K | -986.00K | -1.37M | -1.17M | -1.05M | -1.80M | -4.54M | -1.07M | -1.85K | -302.71K | -428.28K | -519.45K | -381.75K | -160.93K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 | -0.04 | -0.12 | -0.09 | -0.13 | -0.09 | -0.45 | -0.67 | -0.65 | -1.25 |
| EPS Diluted | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 | -0.04 | -0.12 | -0.09 | -0.13 | -0.09 | -0.45 | -0.67 | -0.65 | -1.25 |
| Weighted Avg Shares Out | 137.00M | 136.98M | 136.10M | 101.74M | 88.93M | 85.14M | 50.36M | 39.41M | 12.38M | 14.07K | 3.20M | 951.77K | 777.66K | 584.81K | 129.23K |
| Weighted Avg Shares Out (Dil) | 136.98M | 136.98M | 136.10M | 101.74M | 88.93M | 85.14M | 50.36M | 39.41M | 12.38M | 14.07K | 3.20M | 951.77K | 777.66K | 584.81K | 129.23K |
Source: https://incomestatements.info
Category: Stock Reports